Octreotide

Therapeutic

For treatment of acromegaly and reduction of side effects from cancer chemotherapy

Structural features

SMILES

[H][C@]1(NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@H](CO)[C@@H](C)O)NC(=O)[C@H](N)CC1=CC=CC=C1)[C@@H](C)O

Sequence

fCFwKTCX

Molar mass

1019.25 g/mol

Constitutional members:

8

Natural amino acids

5

D-Amino acids

2

N-terminus

H

C-terminus

OH

Cyclic

yes

Members/cycle

6

Bond to form cycle

side chain-to-side chain (disulfide)

Lipidation

no

Glycosylation

no

Route of administration

SC, IV, IM

Terminal half-life

100 min (SC)

Protein binding

0.65

Absorption and Bioavailability

100% (SC)

References